Next Day Disclosure Return
Filed with HKEX · Stock code 1952 · · 6 pages · English
Earlier from Everest Medicines
- Everest Medicines Announces China NMPA Approval of CARDAMYST® for the Conversion of Acute Symptomatic Episodes of Paroxysmal Supraventricular Tachycardia (PSVT) to Sinus Rhythm in Adults
- Everest Medicines Announces Interim Results for First Half of 2026
- Everest Medicines to Announce 2026 Interim Results and Host Online Investor Call on August 19, 2026
- Everest Medicines Announces Participation in Upcoming Investor Conferences
- Everest Medicines Announces Close of Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib
Later from Everest Medicines
- Establishment of environmental, social and governance committee
- List of directors and their roles and functions
- Terms of reference of the environmental, social and governance committee
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Everest Medicines Appoints Two Veteran mRNA Cancer Vaccine Scientists to Advance Global Clinical Development
Follow Everest Medicines into a list and get an email when it puts out news.
Follow Everest Medicines